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AbstrACt
Objective Urinary tract infections (UTIs) are an important 
reason to consult a general practitioner (GP). Here, we 
describe antimicrobial drug prescribing patterns for UTIs 
by GPs in relation to the Dutch primary care guidelines.
Methods We conducted a population-based cohort study 
in the Dutch Integrated Primary Care Information (IPCI)
database, which encompasses approximately 2.5 million 
patients. All patients aged ≥12 years with at least 1 year 
of follow-up from 1996 to 2014 were extracted from the 
database. The number of prescriptions and choice of drug 
type were investigated over time and in different age 
categories. The choice of antimicrobial drug classes for 
UTIs and the duration of nitrofurantoin use in women were 
compared with the Dutch primary care guidelines of 1989, 
1999, 2005 and 2013.
results The source population comprised 1 755 085 
patients who received 2 019 335 antimicrobial drug 
prescriptions; 401 655 (35.1%) prescriptions were for 
UTIs (45.2% in women and 12.6% in men). The proportion 
of prescriptions for UTIs within all prescriptions with an 
indication code increased from 5.2% in 1996 to 14% in 
2014 in men and from 28% in 1996 to 50% in 2014 in 
women. In men, UTIs were most frequently treated with 
fluoroquinolones during the entire study period, whereas 
fluoroquinolones were only advised as first choice in the 
latest guideline of 2013. In women, UTIs were increasingly 
(p<0.05) treated with nitrofuran derivatives with a 
statistically significant difference after implementation of 
the guideline of 2005. Compliance to the advised duration 
of nitrofurantoin prescriptions in women has increased 
since the guideline of 2005.
Conclusions Antimicrobial drug prescribing for UTIs 
seemed to have increased over time. Prescribing in line 
with the UTI guidelines increased with regard to choice 
and duration of antimicrobial drugs. We showed that 
databases like IPCI, in which prescription and indication 
are monitored, can be valuable antibiotic stewardship 
tools.
IntrOduCtIOn
Urinary tract infections (UTIs) are among 
the most common infections in humans. UTIs 
cause a substantial burden of disease with 
major economic consequences.1 2 In women, 
UTIs are the most common reason to consult 
a general practitioner (GP) in The Nether-
lands with 232 contacts per 1000 women in 
2014. In men, this number was substantially 
lower: 37 contacts per 1000 men.3 
In most cases UTIs are treated with antimi-
crobial drugs. The choice of antimicrobial 
drug depends on the antimicrobial sensi-
tivity of pathogens in urinary cultures (if 
taken), severity of the symptoms and potential 
comorbidities of the individual. Based on the 
resistance patterns of Escherichia coli in The 
Netherlands, Dutch guidelines on the treat-
ment of UTIs have changed several times in the 
last few decades. The latest Dutch guideline 
for the treatment of UTIs in primary care was 
released in 2013 and recommends nitrofuran-
toin as first choice in all patients with cystitis, 
strengths and limitations of this study
 ► This study was conducted in a large database, in-
cluding a substantial part (~15%) of the Dutch popu-
lation, implying that the external validity of our study 
is high.
 ► Every individual in The Netherlands is assigned to 
a single general practitioner (GP), and antimicrobial 
drugs are not sold over the counter. This limits infor-
mation bias, since we had access to all antimicrobial 
drug prescriptions prescribed in primary care.
 ► Improvement of coding discipline in more recent 
years might bias conclusions on total prescribing of 
antimicrobial drugs, but we assume that this bias 
would be similar for all indications. Furthermore, we 
compared the antimicrobial drug prescription data 
for urinary tract infections (UTIs) with antimicrobial 
drug prescription data for other infections.
 ► We analysed the choice of antimicrobial drugs pre-
scribed by GPs in relation to the Dutch guidelines 
on treatment of UTIs and show that database stud-
ies can be used as a tool for good antimicrobial 
stewardship.
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including men. In case of signs of tissue invasion, cipro-
floxacin is recommended as first choice.4 Additionally, the 
recommended duration of treatment has changed. The 
recommended duration of treatment with nitrofurantoin 
for cystitis in women was 3 days in the guidelines of 1989 
and 1999, whereas it has been extended to 5 days in the 
guidelines of 2005 and 2013 (table 1).4–7
Previous research shows that the use of antimicrobial 
drugs in the Netherlands in general has increased since 
2005 until approximately 2012, most prominently in 
elderly patients, but has decreased again since then.8 9 
Since UTIs are a major reason to consult a GP, the use of 
antimicrobial drugs for UTIs contributes significantly to 
total antimicrobial consumption. Therefore, antibiotic 
stewardship focusing on (inappropriate) antimicrobial 
drug prescribing for UTIs is an important target in the fight 
against antimicrobial resistance (AMR). This study aims 
to study the choice of antimicrobial drugs prescribed for 
UTIs by GPs and the duration of nitrofurantoin use over 
time in relation to the Dutch national guidelines (of 1989, 
1999, 2005 and 2013) for the treatment of UTIs in primary 
care using a large electronic primary care database.
MAterIAls And MethOds
data source
This study was conducted using data from the Integrated 
Primary Care Information (IPCI) database, which is a 
longitudinal observational dynamic database containing 
the records from more than 450 general practices 
throughout the Netherlands.10 Briefly, IPCI contains 
the complete electronic medical records of ~2 500 000 
patients, composed of, among others, data on diagnoses 
(coded and free text) and prescriptions coded according 
to the Anatomical Therapeutical Chemical (ATC) classifi-
cation of the WHO.11 The system complies with European 
Union guidelines on the use of data for medical research 
and has been proven valid for pharmacoepidemiolog-
ical studies. More detailed information on IPCI has been 
described elsewhere.10
study population
The study cohort comprised patients aged ≥12 years with 
at least 1 year of valid database history in the IPCI data-
base. The study period was from 1 January 1996 until 
1 January 2015. Follow-up started from the following, 
whichever occurred last: start of the study period, age of 
12 years or reaching a minimum of 12 months of data-
base history. Follow-up ended when a patient left the data-
base or died or at the end of the study period, whichever 
occurred first. Gender, age at the time of prescriptions)
and follow-up time (time of each patient in the database) 
were assessed for all patients.
Prescriptions
From the database, we selected all prescriptions for anti-
microbial drugs prescribed during the study period, 
Table 1 Overview of the treatment of UTIs according to the Dutch guidelines for GPs
1989 1999 2005 2013
Women
  Cystitis Trimethoprim (J01EA) or
sulfamethizol (J01EB) or
nitrofurantoin (J01XE) 
3 days
Nitrofurantoin (J01XE)
3 days or
trimethoprim (J01EA)
First choice: nitrofurantoin 
(J01XE)  5 days
Second choice:
trimethoprim (J01EA)
Third choice:
fosfomycin (J01XX)
First choice: nitrofurantoin 
(J01XE)  5 days
Second choice: fosfomycin 
(J01XX)
Third choice: trimethoprim (J01EA)
  UTI with 
tissue 
invasion
Amoxicillin (J01CA) First choice: amoxicillin–
clavulanic acid (J01CR)
Second choice: 
sulfamethoxazole–
trimethoprim (J01EE)
First choice: amoxicillin– 
clavulanic acid (J01CR)
Second choice: 
sulfamethoxazole–trimethoprim 
(J01EE) or fluoroquinolone 
(J01MA)
First choice: ciprofloxacin (J01MA)
Second choice:
amoxicillin– clavulanic acid 
(J01CR)
Third choice: sulfamethoxazole-
trimethoprim (J01EE)
Men
  Cystitis UTI in men should 
always be considered as 
prostatitis
Nitrofurantoin (J01XE) or
trimethoprim (J01EA)
First choice: nitrofurantoin 
(J01XE)
Second choice:
trimethoprim (J01EA)
First choice: nitrofurantoin (J01XE)
Second choice:
trimethoprim (J01EA)
  UTI with 
tissue 
invasion
Trimethoprim (J01EA) or 
amoxicillin (J01CA)
First choice:
Amoxicillin–clavulanic acid 
(J01CR)
Second choice: 
sulfamethoxazole–
trimethoprim (J01EE)
First choice: amoxicillin–
clavulanic acid (J01CR)
Second choice: 
sulfamethoxazole–trimethoprim 
(J01EE) or fluorochinolone 
(J01MA)
First choice: ciprofloxacin (J01MA)
Second choice:
amoxicillin–clavulanic acid (J01CR)
Third choice: sulfamethoxazole–
trimethoprim (J01EE)
The table shows the treatment of UTIs according to the Dutch guidelines of 1989, 1999, 2005 and 2013. The recommended duration of 
treatment with nitrofurantoin is also described. Please note that information from guidelines on the treatment of pregnant women  and also 
the treatment of risk groups, such as  patients with  diabetes  or abnormalities of the urinary tract, differs and  is not described. Furthermore, 
the treatment duration in men is, in all cases, longer than that  in women. 
GP, general practitioner; UTI, urinary tract infection.  
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using an automatic search on the ATC code ‘J01’, which 
is the ATC code for antimicrobial drugs. All prescrip-
tions of antimicrobial drugs were further categorised 
by ATC drug class, for example, J01AA (tetracyclines) 
(supplementary table s1). We analysed all prescriptions 
of ATC class J01CA (penicillins with extended spectrum), 
J01CR (combinations of penicillins, including beta-lact-
amase inhibitors), J01EA (trimethoprim and derivatives), 
J01EE (combinations of sulfonamides and trimethoprim, 
including derivatives), J01MA (fluoroquinolones), J01XE 
(nitrofuran derivatives) and J01XX (other antimicrobials 
[mainly fosfomycin]). In addition, the duration of all 
prescriptions of nitrofurantoin (J01XE01) (which in the 
Netherlands is only prescribed for UTIs) was assessed.
Indication of use of antimicrobial drugs
Indication of use was assessed through an automatic 
search on disease-specific codes. Antimicrobial drug 
prescriptions were linked to the indication of use through 
a unique patient identifier linking a prescription to a diag-
nosis using the International Classification of Primary 
Care (ICPC)-1 codes (version 5). These ICPC codes were 
categorised in the following indications: UTIs, skin infec-
tions, respiratory infections, ear infections or other infec-
tions (supplementary table s2). All prescriptions without 
an ICPC code were assigned to the group: ‘no code for 
indication of use’. Urethritis was included in the group 
of ‘other’ infections and not in the UTI group because of 
the distinct pathophysiology.
Analyses
The total number of prescriptions for UTIs, ‘other infec-
tions’ (including respiratory infections, skin infections 
and ear infections) and prescriptions without an indica-
tion code were calculated for the complete study time and 
per year. Additionally, the proportion of UTI prescrip-
tions per calendar year was calculated with all antimi-
crobial drug prescriptions with an indication code as 
denominator. Also, all nitrofurantoin prescriptions were 
analysed per year.
Since both the number of users and the total number 
of antimicrobial drug prescriptions are interesting with 
regard to the study of AMR, we studied both. Because 
of the dynamic nature of the study cohort, the annual 
frequency of antimicrobial drug prescriptions was calcu-
lated by dividing the total number of antimicrobial drug 
prescriptions by the total number of person-years (PYs). 
The annual number of users per calendar year was calcu-
lated by dividing all users by the total number of PY in 
that specific year. With regard to the calculation of users, 
if an individual received prescriptions of more than one 
antimicrobial drug class in 1 year, the individual contrib-
uted data to the different classes. However, if an indi-
vidual received two or more prescriptions of the same 
drug in 1 year, the individual contributed only once as a 
user of this specific drug class. The frequency of prescrip-
tions and users were studied by age (12–17, 18–25, 26–35, 
36–45, 46–55, 56–65, 66–75, 76–85 and ≥86 years age 
categories), gender and calendar year. The prescribing 
of antimicrobial drugs by GPs was compared with the 
recommendations according to the national guidelines 
(table 1).4–7
We intended to investigate if improved coding over 
time has influenced the results of the frequency of 
prescribing antimicrobial drug prescriptions for UTIs in 
general, independent of the drug class. Therefore, we 
also studied the frequency of nitrofurantoin prescriptions 
over time (since nitrofurantoin was only prescribed for 
UTIs), and we studied the proportion of prescriptions for 
UTIs within total prescriptions with an indication code 
(thus including all antimicrobial drug prescriptions with 
information on indication of use).
Furthermore, all nitrofurantoin prescriptions 
prescribed to women during the study period were 
selected, and duration of use was categorised in 3, 5, 7 
days or in ‘other’ (when the number of days of use was 
unknown or different from 3, 5, or 7 days). The propor-
tion of each category with the total number of prescrip-
tions of nitrofurantoin in women as denominator was 
calculated by year.
Finally, we used a time series ARIMA model (in SPSS 
V.24) in order to determine the effect of the implemen-
tation of the guideline of 2005.12 The calendar year was 
first univariably added to the analysis to study differences 
of antimicrobial drug prescribing over time. Next, we ran 
a model including calendar year and the intervention 
(implementation of the guideline). When the p value of 
the interaction term was <0.05, the difference in slope 
before and after the implementation of the guideline was 
significant, implying a significant effect of the implemen-
tation of this guideline.
Patients and public involvement
No patients were involved in any stage of this study.
results
The study population comprised 1 755 085 patients aged 
≥12 years with a mean follow-up time of 3.31 years. A 
total of 671 251 (38.2%) patients were prescribed at least 
one antimicrobial drug during the study period: 271 772 
(40.5%) men and 399 479 (59.5%) women. In total, 
they received 2 019 335 antimicrobial drug prescriptions 
(mean of 3 prescriptions per person) during the study 
period. Of these prescriptions, 1 144 810 (56.7%) could 
be linked to an indication, namely, 528 464 (46.2%) anti-
microbial drug prescriptions for respiratory infections; 
401 655 (35.1%) for UTIs; 157 900 (13.8%) for skin infec-
tions; 29 984 (2.6%) for ear infections and 26 807 (2.3%) 
for ‘other’ infections.
Antimicrobial drug prescriptions for utIs by calendar year
For all years combined and only considering those 
prescriptions with indication of use, prescriptions for UTIs 
were 12.6% of the total prescriptions in men and 45.2% 
in women. The total number of prescriptions per year for 
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UTIs increased from 9 (men) and 88 (women) prescrip-
tions per 1000 PY in 1996 to 19 and 153 prescriptions per 
1000 PY, respectively, in 2014. However, especially at the 
end of the study period, prescriptions without indication 
codes decreased (figure 1). To control for improvement 
of coding over time, we studied the total number of nitro-
furantoin prescriptions, which in the Netherlands is only 
prescribed for UTIs. In women more clearly than in men, 
we see a flattening or even decrease of the number of 
non-coded nitrofurantoin prescriptions, whereas the 
number of coded and total nitrofurantoin prescriptions 
increased (supplementary figure s1). Moreover, we calcu-
lated the proportion of antimicrobial drug prescriptions 
for UTIs with all antimicrobial drug prescriptions with an 
indication code (for all indications) as denominator. In 
this analysis, the proportion of antimicrobial drugs for 
UTIs increased from 5.2% in 1996 to 14% in 2014 for 
men and from 28% in 1996 to 50% in 2014 for women 
(supplementary figure s2).
Fluoroquinolones (J01MA) are the most commonly 
prescribed antimicrobial drugs in men with UTIs with 
no clear increase or decrease over time. Other frequently 
prescribed antimicrobial drugs were combinations of 
sulfonamides and trimethoprim (J01EE) and combina-
tions of penicillins, including beta-lactamase inhibitors 
(J01CR); the last group increased significantly over time 
until 2013. Also, in men, the number of prescriptions of 
nitrofuran derivatives increased significantly from 0.4 
prescriptions per 1000 PY in 1996 to 6.2 prescriptions 
per 1000 PY in 2014. In women, nitrofuran derivatives 
(J01XE) were clearly the most frequently prescribed 
drugs since 1999, with a strong and significant increase in 
the last years from 52 prescriptions per 1000 PY in 2008 
to 98 prescriptions per 1000 PY in 2014. They increasingly 
replaced the prescriptions of trimethoprim and deriv-
atives (J01EA) and fluoroquinolones (J01MA), which 
were also commonly prescribed in women. Also, the 
prescriptions of combinations of penicillins, including 
Figure 1 The number of users and prescriptions of antimicrobial drugs for urinary tract infections, other infections and 
infections without indication code in the period 1996–2014. 
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beta-lactamase inhibitors (J01CR) and fosfomycin, signifi-
cantly increased, for fosfomycin mainly in most recent 
years (figure 2).
Choice of antimicrobial drug prescription in relation to the 
recommendations of the national primary care guidelines
The implementation of the Dutch guideline on the 
treatment of UTIs of 2005 was associated in women with 
a significant decrease in the slope of prescriptions of 
trimethoprim and derivatives (J01EA) and an increase 
in nitrofuran derivative (J01XE) prescriptions. Unfortu-
nately, we did not have sufficient data before 1999 and 
after 2013 to study the implementation of the other 
guidelines. For men, no significant effects were found of 
the implementation of the guidelines on the slope of any 
antimicrobial drug prescriptions.
Prescriptions of antimicrobial drugs for utIs by age groups
Both in men and women, an increase in the total number 
of UTI prescriptions was observed for increasing age cate-
gory. In women, the number of prescriptions in all age 
groups is higher than that in men, with nitrofuran deriv-
atives (J01XE) as the most prescribed antimicrobial drug 
in all age groups, followed by fluoroquinolones (J01MA) 
and trimethoprim and derivatives (J01EA). In men, 
fluoroquinolones (J01MA) were the most frequently 
prescribed antimicrobial drugs in most age groups, 
followed by nitrofuran derivatives (J01XE) and combina-
tions of penicillins, including beta-lactamase inhibitors 
(J01CR) (figure 3).
Analysing the total number of prescriptions for UTIs 
(J01—antibacterials for systemic use) per age category, 
we observed an increase in the past years for all age cate-
gories, but most prominent in the higher age categories 
(supplementary figure s3).
Changes in duration of nitrofurantoin prescriptions
In total, 215 531 prescriptions of nitrofurantoin with an 
ICPC code for UTIs were prescribed to women in the 
study period. In line with a change in recommended 
duration from 3 to 5 days in 2005, the proportion of 
prescriptions with a duration of 5 days increased 
strongly from 2005 onwards, while the proportion of 
prescriptions with a duration of 3 days became scarce. 
The proportion of prescriptions with a duration of 7 
days decreased from 33% in 1996 to 18% in 2014. The 
proportion of prescriptions with a duration other than 
3, 5 or 7 days (defined as ‘other duration’) remained 
stable over time, with a proportion ranging between 6% 
and 10% (figure 4).
Figure 2 The number of users and prescriptions of antimicrobial drugs for urinary tract infections in the period 1996–2014. 
Note that the scale of the y-axis differs between men and women.
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dIsCussIOn
In this study, we investigated the prescribing of anti-
microbial drugs for UTIs in primary care during the 
study period from 1 January 1996 to 1 January 2015 and 
compared this with the recommendations in the Dutch 
primary care guidelines. These guidelines are actively 
distributed by the Dutch College of General Practitioners.
During the study period, nitrofurantoin was shown to 
be the most prescribed drug for the treatment of UTIs, 
especially in women, and increasingly in men. The Dutch 
guidelines of 1989 indicated nitrofurantoin as one of the 
options for women, whereas it was suggested as option 
for both men and women in the guideline of 1999 and 
as the first-choice drug for cystitis in the 2005 and 2013 
guideline. This is reflected in our findings; we observed 
an increase in nitrofurantoin prescriptions in men and 
women since 1999, with a steep and significant increase 
since 2005. In this period, nitrofurantoin replaced 
trimethoprim in women, which significantly decreased 
after 2005. Furthermore, in the guidelines of 1999 and 
2005, amoxicillin–clavulanic acid was recommended 
for UTIs with tissue invasion, whereas amoxicillin (or 
trimethoprim in men) was recommended for UTIs with 
tissue invasion in the guideline prior to 1999. In men 
and women, a significant increase of combinations of 
penicillins, including beta-lactamase inhibitors such as 
amoxicillin–clavulanic acid, was shown during the study 
period. In men, a flattening was seen from 2012, just 
before the guideline of 2013, which recommended cipro-
floxacin as first choice.
We also studied the compliance of GPs to guidelines 
with regard to the duration of nitrofurantoin prescribing 
in women. The recommended duration increased from 3 
to 5 days in 2005, which is reflected in our findings, indi-
cating an increase in adherence to the guidelines by GPs, 
mainly since the guidelines of 2005 and 2013.4–7 A devia-
tion from the UTI guidelines was observed with regard to 
the prescribing of fluoroquinolones. Fluoroquinolones, 
in particular, ciprofloxacin, were only advised as first-
choice drug for UTIs with tissue invasion from 2013 on 
(in 2005, it was second choice, and in 1989, its use was 
discouraged), whereas in men, these drugs were the 
most frequently described antimicrobial drug during the 
complete study period. In women, we saw a significant 
decrease over time, suggesting an increase of compliance 
of GPs over time.
A study in another Dutch GP database investigated 
antimicrobial prescribing for several infections during 
2001 and showed that approximately 75% of the prescrip-
tions for cystitis were first-choice drugs (nitrofurantoin or 
Figure 3 The number of users and prescriptions of antimicrobial drugs for urinary tract infections per age group. Note that the 
scale of the y-axis differs between men and women.
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trimethoprim) according to guidelines.13 The percentage 
of first-choice drug prescriptions in our study in 2001 is 
comparable (approximately 67% for women). A smaller 
study from 2009 in 970 non-pregnant women of ≥ 11 years 
with cystitis determined that 66% were prescribed nitro-
furantoin, whereas we found a proportion of 57% in all 
women in 2009.14 Our proportion is somewhat smaller, 
possibly because we did not distinguish between cystitis 
and pyelonephritis, since a proportion of the prescrip-
tions had an indication code for both. However, the 
sample size of the other study is much smaller, resulting 
in more uncertainty around the true prevalence of anti-
microbial drug use.
As part of new health quality standards, GPs are encour-
aged to improve disease coding, a phenomenon also 
observed in other countries. This might in part explain the 
increase in total prescriptions for UTIs, which is under-
lined by our finding that the number of prescriptions 
for nitrofurantoin without an indication code seemed to 
decrease, especially in women since approximately 2007. 
To control for this bias, we analysed UTI prescriptions as 
a proportion of the total number of antimicrobial drug 
prescriptions with an indication code (thus excluding 
prescriptions without a disease code). Yet, we observed 
that the increase of prescriptions was larger for UTIs 
than for other indications. This increase in antimicrobial 
drug prescribing for the treatment of UTIs is supported 
by other literature. According to the NIVEL (Nether-
lands Institute for Health Services Research) registration, 
the number of contacts with a GP for UTIs increased 
(especially in women) from 185 per 1000 in 2012 to 295 
per 1000 in 2015.3 This was confirmed by another large 
Dutch GP database, showing an increase of GP visits for 
UTIs and antimicrobial drug prescriptions for UTIs in 
the period 2007–2010.15 16 This increase of use of anti-
microbial drugs for UTIs might partly be explained by 
ageing of the population. Indeed, we showed that anti-
microbial drugs for UTIs were especially prescribed to 
patients in older age categories. Additionally, a Dutch 
study from 2012 also showed an increase of antimicrobial 
drug prescribing by age, and an increase of total prescrip-
tions of antimicrobial drugs to elderly: in 2000, 9% of 
patients above 80 years had at least one prescription, 
which increased to 22% in 2009.8 However, ageing of the 
population cannot solely explain the increase, since we 
also showed an increase in prescriptions of antimicrobial 
drugs in younger age groups. Possible explanations might 
be that more patients suffer from recurrent UTIs, that 
patients more frequently visit their GP in case of a UTI 
or that GPs more easily prescribe antimicrobial drugs for 
UTIs, but this has to be elucidated in future studies.
One of the strengths of this study is that we used a large 
population-based cohort from a database with detailed 
information on prescriptions and where information is 
collected as part of routine clinical care, reducing the risk 
of selection and information bias. We used these data to 
show that they can be of importance in studying antibiotic 
stewardship. Unfortunately, because of confidentiality, 
we could not study differences in prescribing patterns 
by region nor by GP characteristics such as age and/or 
Figure 4 The proportion of the different durations of nitrofurantoin prescriptions in women in the period 1996–2014. The 
proportion of prescriptions of nitrofurantoin (J01XXE01) with a duration of 3, 5 and 7 days or ‘other’ duration (unequal to 3, 
5 and 7 days or unknown) with all these nitrofurantoin prescriptions as denominator. Until 2005, the duration recommended by 
the guideline was 3 days, whereas since the guideline of 2005, the advised duration was 5 days.
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gender. Additionally, although we found that antimicro-
bial drugs were increasingly prescribed according to the 
guidelines, the study design did not allow us to investigate 
the reasons behind deviations from the guidelines. This 
is of interest and should be studied further, eventually by 
qualitative prospective research to distinguish between 
forced deviations caused by resistant pathogens and other 
deviations, which should be diminished to promote good 
antimicrobial stewardship.
Reducing the use of antimicrobial drugs is important, 
since the drawback of treating infections with antimicro-
bial drugs is the development of AMR.17 Patients suffering 
from infections caused by resistant bacteria have an 
increased risk of a worse clinical outcome and death.17 
Moreover, AMR leads to an increase in healthcare costs, 
which has been estimated to be 1.5 billion euros in EU 
every year.18 19 Misuse and overuse of antimicrobial drugs 
are the most important risk factors of AMR worldwide.20 
Therefore, antimicrobial stewardship programmes have 
been developed, aiming to optimise the prescribing of 
antimicrobial drugs and to minimise misuse and overuse 
in order to minimise AMR.21 Our study demonstrates that 
databases with antimicrobial drug prescriptions and indi-
cations are useful for surveillance of antimicrobial drug 
prescriptions over time. In future, information gathered 
in such databases should be provided to GP practices as 
part of antibiotic stewardship in primary care.
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